Market Cap 6.84B
Revenue (ttm) 7.80B
Net Income (ttm) 169.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 9.78
Profit Margin 2.18%
Debt to Equity Ratio 1.27
Volume 672,100
Avg Vol 799,436
Day's Range N/A - N/A
Shares Out 687.56M
Stochastic %K 42%
Beta 0.69
Analysts Sell
Price Target $12.15

Company Profile

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clo...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 34 935 712 200
Fax: 34 938 008 000
Address:
Avinguda de la Generalitat 152-158, Parque Empresarial Can Sant Joan Sant Cugat del Valles, Barcelona, Spain
NVDAMillionaire
NVDAMillionaire Oct. 3 at 2:31 PM
$GRFS Brilliant piece that captures GRFS's situation perfectly. So if you want to update your understanding of GRFS or get to know GRFS better, this is essential reading. https://beyondspx.com/quote/GRFS/analysis/grifols-nasdaq-grfs-plasma-powerhouse-unleashes-growth-and-deleveraging-momentum
0 · Reply
highnihilism
highnihilism Oct. 1 at 9:26 AM
$IEZ iShares U.S. Oil Equipment & Services ETF Trade Count: 12 | Total $: 3.5 K | 2.85 × 90-Day Avg $: 1.2 K | Call $: 3.4 K | Put $: 90 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $SOBO South Bow Trade Count: 11 | Total $: 3.4 K | 0.60 × 90-Day Avg $: 5.7 K | Call $: 3.4 K | Put $: 40 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $GRFS Grifols S.A. Trade Count: 2 | Total $: 3.4 K | 0.31 × 90-Day Avg $: 11 K | Call $: 3.4 K | Put $: 30 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $CADL Candel Therapeutics Trade Count: 20 | Total $: 3.4 K | 0.09 × 90-Day Avg $: 38.4 K | Call $: 3.4 K | Put $: 0 | % Single-Leg: 97% | % Multi-Leg: 0% | % Contingent: 3%
0 · Reply
topstockalerts
topstockalerts Sep. 26 at 5:04 PM
U.S. plans for new pharmaceutical tariffs are seen as negative due to uncertainty but could be an “opportunity” for Grifols, which is fully vertically integrated in the U.S. Banco Sabadell analysts noted the 100% tariff announcement on foreign branded or patented drugs unless companies establish U.S. manufacturing. While the news creates noise, details remain unclear, especially for firms already present in the U.S. Sanofi has announced $ 20B investment in the U.S. through 2030. Grifols is expected to face no negative impact, with ~70% of plasma collection and ~65% of production capacity in the U.S. Analysts see tariffs as a potential advantage for Grifols, the only fully vertically integrated hemoderivatives company in the country. Almirall’s impact would be minimal (~4.5% of sales in the U.S.), and Rovi is unlikely to be affected due to no direct distribution or branded products in the U.S. $GRFS $SNY $ALM $ROVI
0 · Reply
TradeJizzer
TradeJizzer Aug. 14 at 2:18 AM
$GRFS Breaking on X: Grifols just got busted for taking donated blood and selling it. This may gap down in the am.
0 · Reply
Doozio
Doozio Aug. 2 at 6:15 PM
$GRFS dips appears a 🎁 during 🐒🍌🧠⏰♾️
0 · Reply
RunnerSignals
RunnerSignals Jul. 29 at 9:07 PM
$CELC $GRFS $HIMS $ECX $ODP Comeback Kings shook off the midday dips and closed strong
0 · Reply
DonCorleone77
DonCorleone77 Jul. 29 at 5:17 PM
$GRFS Grifols reports Q2 revenue EUR 1.89B vs. EUR 1.79B last quarter -- Q2 profit EUR 191M vs. EUR 115M last quarter. -- Reinstates dividend of EUR 0.15 per share -- Affirms 2025 guidance from capital markets day
0 · Reply
BeefStewart
BeefStewart Jul. 17 at 8:14 PM
$CERS Looks like some plasma-related stocks are just lagging $ADMA $GRFS ....
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 24 at 9:07 PM
$GRFS Grifols paid a higher price to buy blood plasma from an entity linked to its controlling family than from third-party suppliers, according to a regulator’s findings submitted in a court case ….
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 24 at 6:59 AM
$GRFS Grifols pagó hasta un 39% más para comprar plasma a Scranton Según las conclusiones de un regulador presentadas en un caso judicial, la farmacéutica española también acordó pagar a Scranton un margen fijo del 16,5% sobre los costes Bad news
0 · Reply
Latest News on GRFS
Grifols: Significant Upside Likely Materializing

Oct 2, 2025, 9:23 PM EDT - 2 days ago

Grifols: Significant Upside Likely Materializing


Grifols: If This Works Out, It Has Massive Upside

May 22, 2025, 12:09 PM EDT - 4 months ago

Grifols: If This Works Out, It Has Massive Upside


Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript

May 12, 2025, 4:51 PM EDT - 5 months ago

Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript


Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale

Feb 27, 2025, 12:58 PM EST - 7 months ago

Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale


Grifols expects to boost revenue and free cash flow, shares soar

Feb 27, 2025, 11:23 AM EST - 7 months ago

Grifols expects to boost revenue and free cash flow, shares soar


Grifols' sales rise over 10% in 2024, above target

Feb 26, 2025, 12:18 PM EST - 7 months ago

Grifols' sales rise over 10% in 2024, above target


Flat Footed Calls for Prompt Governance Overhaul at Grifols

Dec 10, 2024, 12:23 PM EST - 10 months ago

Flat Footed Calls for Prompt Governance Overhaul at Grifols


Grifols: More Attractive Than In A Very Long Time

Nov 29, 2024, 12:30 PM EST - 11 months ago

Grifols: More Attractive Than In A Very Long Time


Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?

Nov 29, 2024, 9:29 AM EST - 11 months ago

Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?


Grifols: Brookfields potential $6.8 bln offer undervalues the firm

Nov 19, 2024, 8:25 AM EST - 11 months ago

Grifols: Brookfields potential $6.8 bln offer undervalues the firm


Significant Shareholders Exercise Right to Grifols Board Seat

Sep 19, 2024, 3:23 PM EDT - 1 year ago

Significant Shareholders Exercise Right to Grifols Board Seat


NVDAMillionaire
NVDAMillionaire Oct. 3 at 2:31 PM
$GRFS Brilliant piece that captures GRFS's situation perfectly. So if you want to update your understanding of GRFS or get to know GRFS better, this is essential reading. https://beyondspx.com/quote/GRFS/analysis/grifols-nasdaq-grfs-plasma-powerhouse-unleashes-growth-and-deleveraging-momentum
0 · Reply
highnihilism
highnihilism Oct. 1 at 9:26 AM
$IEZ iShares U.S. Oil Equipment & Services ETF Trade Count: 12 | Total $: 3.5 K | 2.85 × 90-Day Avg $: 1.2 K | Call $: 3.4 K | Put $: 90 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $SOBO South Bow Trade Count: 11 | Total $: 3.4 K | 0.60 × 90-Day Avg $: 5.7 K | Call $: 3.4 K | Put $: 40 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $GRFS Grifols S.A. Trade Count: 2 | Total $: 3.4 K | 0.31 × 90-Day Avg $: 11 K | Call $: 3.4 K | Put $: 30 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $CADL Candel Therapeutics Trade Count: 20 | Total $: 3.4 K | 0.09 × 90-Day Avg $: 38.4 K | Call $: 3.4 K | Put $: 0 | % Single-Leg: 97% | % Multi-Leg: 0% | % Contingent: 3%
0 · Reply
topstockalerts
topstockalerts Sep. 26 at 5:04 PM
U.S. plans for new pharmaceutical tariffs are seen as negative due to uncertainty but could be an “opportunity” for Grifols, which is fully vertically integrated in the U.S. Banco Sabadell analysts noted the 100% tariff announcement on foreign branded or patented drugs unless companies establish U.S. manufacturing. While the news creates noise, details remain unclear, especially for firms already present in the U.S. Sanofi has announced $ 20B investment in the U.S. through 2030. Grifols is expected to face no negative impact, with ~70% of plasma collection and ~65% of production capacity in the U.S. Analysts see tariffs as a potential advantage for Grifols, the only fully vertically integrated hemoderivatives company in the country. Almirall’s impact would be minimal (~4.5% of sales in the U.S.), and Rovi is unlikely to be affected due to no direct distribution or branded products in the U.S. $GRFS $SNY $ALM $ROVI
0 · Reply
TradeJizzer
TradeJizzer Aug. 14 at 2:18 AM
$GRFS Breaking on X: Grifols just got busted for taking donated blood and selling it. This may gap down in the am.
0 · Reply
Doozio
Doozio Aug. 2 at 6:15 PM
$GRFS dips appears a 🎁 during 🐒🍌🧠⏰♾️
0 · Reply
RunnerSignals
RunnerSignals Jul. 29 at 9:07 PM
$CELC $GRFS $HIMS $ECX $ODP Comeback Kings shook off the midday dips and closed strong
0 · Reply
DonCorleone77
DonCorleone77 Jul. 29 at 5:17 PM
$GRFS Grifols reports Q2 revenue EUR 1.89B vs. EUR 1.79B last quarter -- Q2 profit EUR 191M vs. EUR 115M last quarter. -- Reinstates dividend of EUR 0.15 per share -- Affirms 2025 guidance from capital markets day
0 · Reply
BeefStewart
BeefStewart Jul. 17 at 8:14 PM
$CERS Looks like some plasma-related stocks are just lagging $ADMA $GRFS ....
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 24 at 9:07 PM
$GRFS Grifols paid a higher price to buy blood plasma from an entity linked to its controlling family than from third-party suppliers, according to a regulator’s findings submitted in a court case ….
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 24 at 6:59 AM
$GRFS Grifols pagó hasta un 39% más para comprar plasma a Scranton Según las conclusiones de un regulador presentadas en un caso judicial, la farmacéutica española también acordó pagar a Scranton un margen fijo del 16,5% sobre los costes Bad news
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 23 at 8:15 PM
$GRFS bad news ? Weird day
0 · Reply
JarvisFlow
JarvisFlow Jun. 17 at 1:00 PM
JP Morgan updates rating for Grifols ( $GRFS ) to Neutral, target set at 7.6 → 10.3.
0 · Reply
DonCorleone77
DonCorleone77 May. 30 at 11:14 AM
$GRFS U.S. court rules to go on with Grifol lawsuit against Gotham City, Reuters says A New York court has found enough evidence to continue with the defamation lawsuit filed by Grifols against short seller Gotham City Research, Reuters reports. The Federal District Court for the Southern District of New York rejected Gotham City's request to dismiss the lawsuit, but did narrow it by rejecting some claims.
0 · Reply
ZacksResearch
ZacksResearch May. 28 at 2:57 PM
After a strong start, is $ADMA still the best bet, or is $GRFS taking the lead? 🏆 💡 ADMA boasts robust Asceniv demand and 15.9% gains in 2025, but trades at a pricey 25.48X forward earnings. 📈 Meanwhile, GRFS, with its wider portfolio and Zacks Rank #2 (Buy), offers a cheaper 7.19X valuation and a significant EPS improvement of 296% in 2025. Discover which stock could be your next winner 👉 https://www.zacks.com/commentary/2478303/adma-biologics-vs-grifols-which-plasma-therapy-stock-is-the-better-buy?cid=sm-stocktwits-2-2478303-body&ADID=SYND_STOCKTWITS_TWEET_2_2478303_BODY
0 · Reply
ZacksResearch
ZacksResearch May. 28 at 1:06 PM
At current levels, $GRFS scores over $ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum. Explore further: https://www.zacks.com/stock/news/2478303/adma-biologics-vs-grifols-which-plasma-therapy-stock-is-the-better-buy?cid=sm-stocktwits-2-2478303-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2478303_TEASER
0 · Reply
RunnerSignals
RunnerSignals May. 22 at 9:39 PM
Fresh Upgrades and Downgrades After-Hours! $CR $INGN $GRFS $MU $SWK and more in play! Analysts reshuffled the deck - who's your pick going into Friday? stocksrunner.com/news/2025-05-22-thursday-analyst-upgrades-and-downgrades
0 · Reply
Messerschmittbf109
Messerschmittbf109 May. 10 at 6:04 AM
$GRFS bad candle last session
0 · Reply
Biotekman
Biotekman Apr. 17 at 3:43 PM
$GRFS Just initiated a position. They have a "2029 plan" to reduce the debt. Promising.
2 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 15 at 6:44 PM
$GRFS take over soon
0 · Reply
LewisWay
LewisWay Apr. 15 at 3:59 PM
$GRFS 🤫🤩 Holly s... check this out... I remember what they've did last time, it's a retail war against hedge funds... I'm in. BUY BUY BUY 🥳🤛🧨🚀🚀🚀
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 14 at 8:10 PM
$GRFS $JSPR take over .. this is the end of
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 14 at 7:31 PM
$GRFS over SMA.
0 · Reply